FILING ANALYSIS · THURSDAY, NOVEMBER 12
4D Molecular Therapeutics, Inc. FDMT — 8-K: Results of Operations and Financial Condition
neutral
The company reported Q3 2026 financial results, completed enrollment and randomization of the 4FRONT-2 Global Phase 3 clinical trial, and initiated the 4SIGHT Global Phase 3 clinical trial of 4D-150 in DME, with $375 million in cash expected to fund operations into H2 2028. No quantified surprises were disclosed in the filing.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →